🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

The oral abstracts on menin is now live! Growing interest in menin as a therapeutic target is remarkable, and this year’s results are pushing the boundaries even further. Stay tuned for some intriguing insights #menininhibitors #ASH24 ⁦ASH⁩

Ziftomenib shows CR rate of 100% in NPM1-mutated and 83% in KMT2A-rearranged AML in the KO-MEN-007 combination trial! 76% & 75% MRD negative💥 A major leap forward for targeted therapies in AML. #AML #MeninInhibitors #ASH24 Amer Zeidan MBBS,MHS ‏عامر زيدان

It’s a proud moment for us! ASH awards 2024 Mentor award to Dr.Schiffer. #ASH24 ASH Wayne State University Karmanos Cancer Institute

Excited to share our latest findings! Join us this evening at Poster 2768 as sandhya dhiman presents on menin interaction and nuclear export inhibition in NPM1-mutant AML.#ASH24 ASH

My favorite one from the plenary #ASH24 ASH

Congrats on the Abstract Achievement Award! XPO1 and menin inhibition is synergistic in NPM1 mutant AML #ASH24 ASH sandhya dhiman Wayne State University Karmanos Cancer Institute

Interesting year long work will be shared by Vik Dhillon at the oral abstract session 615 from 245 PM today! Please stop by to learn more #ASH24 ASH Jeff Aguilar

Exciting updates from Vik Dhillon! latest insights on molecular characteristics of RAS mutations and an innovative ML-based treatment response prediction system. #ASH24 ASH

Happening now! ⁦tariqkewan⁩ delivered a Great talk! #ASH24 ⁦ASH⁩ ⁦Valeria Visconte⁩ ⁦Carmelo Gurnari⁩

Congratulations Vik Dhillon Abdulmoiz! Differential prognostic impact of NPM1-MT AML underscores the need for age-adapted risk stratification models MDPI Jeff Aguilar Sushmitha Nanja Reddy Julie Boerner Carmelo Gurnari Waled Bahaj, MD tariqkewan Valeria Visconte

BIG NEWS!

Check out our comprehensive review on #AML from an MD Anderson Cancer Center perspective, " Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challenges" published in ACS Journal Cancer acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… #leusm

🌞 Day 1 afternoon sessions are starting soon at the 2025 DAVA Whistler Summit! Get ready for more enlightening talks and discussions. Stay engaged and informed! Practicing HCPs are welcome to join in through our virtual platform! dava.link/whistler2025 #DAVAWhistler #Oncology

It’s a nice gesture from @BloodJournal to recognize their reviewers!

Magrolimab once showed promise in TP53-mutated AML, but recent data didn’t meet the mark, and development has been halted. A tough reminder of the challenges in translating early hope into clinical success. #AML onlinelibrary.wiley.com/doi/10.1002/jh…

Resumes shouldn't just showcase our success. They should feature our struggles too. No one's life is a highlight reel. Character isn't visible in our triumphs alone—it's revealed by the hardships we endure and the challenges we conquer. Here’s my lowlight reel. What's on yours?

First time at #EHA and first time in Milan! Excited to present our research and learn from amazing colleagues. Can’t wait for the great lineup of talks on menin! #EHA2025

Remarkable work by Yash Pershad and team on CHIP dynamics over 16 years in ~7,000 women out now in Blood Journals Portfolio! Longitudinal CHIP studies remain rare - this depth of follow-up is invaluable. Correlates and Consequences of Clonal Hematopoiesis Expansion Rate: A 16-Year

Shortened VEN duration (2 wks C1 f/b 1 wk from C2)w/ VEN+AZA shows similar efficacy to full-dose: •dnAML: CRc 70%, mOS 19.4 mo (vs Viale-A: 66.8%, 14.7 mo) •R/R AML: CRc 60%, mOS 13.1 mo (vs VenEx sAML+R/R: 39%, 8.4 mo) Grade ≥3 AEs slightly reduced vs Viale-A. #EHA2025

ITA air from Toronto 2 Milan felt like an airport storage unit on wheels, distant boarding gate, stained seats & cutlery, duct-taped panels with a seat rattle/ percussion solo. But the crew? Michelin-star level kindness. Return was a Business class Bliss. ✈️🇨🇦🇮🇹 ITA Airways